NCT02531516 2026-03-19
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Aragon Pharmaceuticals, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Genentech, Inc.
AstraZeneca
Hoffmann-La Roche
AstraZeneca
Abbott